Clinical Trials Logo

Safety Issues clinical trials

View clinical trials related to Safety Issues.

Filter by:

NCT ID: NCT06095804 Not yet recruiting - Safety Issues Clinical Trials

Clinical Pilot Study of the Percutaneous Ultrasound Jejunostomy Procedure

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the feasibility and performance of the Percutaneous Ultrasound Jejunostomy (PUJ) procedure that utilizes a novel device (PUMA-J System) in conjunction with widely available ultrasound technology and endoscopic guidance. The procedure will be performed in up to 10 eligible subjects. Patients will be followed for 2 days following performance of PUJ to assess for potential complications.

NCT ID: NCT06087913 Recruiting - Safety Issues Clinical Trials

Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

Start date: November 8, 2023
Phase: Phase 1
Study type: Interventional

MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.

NCT ID: NCT06076512 Recruiting - Chronic Pain Clinical Trials

Pain Clinic Provides Public Health Safety

Start date: February 2, 2018
Phase:
Study type: Observational

Chronic pain is associated with psychological disorders; which may affect a patient's socioeconomic, legal, domestic, and employment situations. This prospective observational study evaluates the impact of pain management on patients' health, social, economic, and employment status. It explores the impact of pain clinic services on patients' mental health, family health, public health, road safety, addiction situation, public safety, injury rehabilitation and employment situation.

NCT ID: NCT06053853 Completed - Safety Issues Clinical Trials

Post Marketing Surveillance of Diphtheria Antitoxin (DAT)

Start date: January 31, 2023
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the safety profile of Diphtheria Antitoxin

NCT ID: NCT06006078 Completed - Safety Issues Clinical Trials

Aersosolization During Upper Endoscopy

Start date: August 31, 2021
Phase: N/A
Study type: Interventional

Given the current Covid-19 pandemic alongside the lack of evidence on aerosolization during upper endoscopy the investigators are conducting a randomized controlled trial seeking to assess both the level of aerosolization that occurs during these procedures along with determining if utilization of an endoscopic patient face-masks reduces the level of aerosolized particles. The protocol includes the use of a commercially available particle counter the investigators are employing for the measurement of aerosols before, during, and after anesthesia assisted upper endoscopic procedures. The investigators are recruiting patients undergoing these procedures with a target of 30 patients undergoing endoscopy without a facemask and 30 patients undergoing endoscopy with one.

NCT ID: NCT05978908 Recruiting - Safety Issues Clinical Trials

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

Start date: February 20, 2024
Phase: Phase 1
Study type: Interventional

A Phase I, Randomized, Double-Blind, Placebo-Controlled, First-in-human, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of retro enversio (RT) thymopentin in Healthy Adult Participants and Patients with Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT05973812 Completed - Safety Issues Clinical Trials

Safety of Bifidobacterium Breve PS1 for Infants

Start date: December 12, 2012
Phase: N/A
Study type: Interventional

The objective of this work was the characterization of the probiotic potential of Bifidobacterium breve PS1, a strain originally isolated from human milk. Subsequently, its safety and tolerance were evaluated in a trial including healthy, formula-fed 3-months-old infants. A total of 187 infants were randomized into two groups: probiotic group (PG) and control group (CG). Both groups received the same infant formula but, in the case of the PG, it was supplemented with the strain. A total of 160 infants (80 per group) completed the three months of intervention.

NCT ID: NCT05967325 Recruiting - Safety Issues Clinical Trials

SVF Combined With Functional Self-assembling Peptide Nanofiber Hydrogels in the Treatment of Spinal Cord Injury

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

Traumatic spinal cord injury (SCI) is a severe medical problem experienced by people worldwide with high mortality and long term morbidity. Although progress has been made in understanding cellular and molecular mechanisms of SCI, treatment and management protocols aimed at ameliorating neurologic damage in patients remain ineffective. Cells and biomaterials offer new hope for the treatment of SCI. Up to now, there have been many studies on the treatment of SCI using cells and biomaterials. Stromal Vascular Fraction (SVF) is a heterogeneous mixture of cells obtained from adipose tissue. These cells include adipose-derived stem cells, endothelial cells, endothelial progenitor cells, pericytes, T cells, and other immune cells. SVF has strong self-renewal, proliferation and differentiation potential, it can replace necrotic cells and synthesize a variety of bioactive factors through paracrine and autocrine, activate cell and vascular regeneration pathways. Therefore, SVF shows significant advantages. The sequence of functional self-assembling peptide nanofiber hydrogels (hereinafter referred to as hydrogels) is HGF(RADA)4RIKVAV (H: histidine; G: Glycine; F: phenylalanine; R: arginine; A: Alanine; D: aspartic acid; I: isoleucine; K: Lysine; V: valerine). The hydrogel is based on the short peptide RADA16 ((RADA)4, which is already available in the product PuramatrixTM for clinical hemostasis and cell culture, but the aqueous solution of PuramatrixTM is acidic which harms cells and tissues upon direct contact. While the hydrogels in this study is pH neutral and does not harm cells and tissues. Articles published by the provider demonstrate that hydrogels can support 3D stem cell growth, have good biocompatibility in vivo (animal spinal cord), and promote neural regeneration after SCI. The chemical structure of the hydrogels is simple and clear, and the degradation product is amino acid. Therefore, SVF and the hydrogel from functional self-assembling peptide are combined for SCI repair in the study.

NCT ID: NCT05916898 Recruiting - Safety Issues Clinical Trials

The Lower Silesia Shockwave Registry

LSSR
Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two cooperating cardiac centers (Department of Cardiology, The Copper Health Centre, Lubin Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).

NCT ID: NCT05901012 Completed - Healthy Volunteers Clinical Trials

Safety and Tolerability of DMT in Healthy Adults

Start date: April 26, 2023
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine (DMT) in healthy individuals.